Amanta Healthcare IPO GMP: What You Need to Know
The buzz around IPOs is always exciting, and this week it’s all about Amanta Healthcare, a pharma company stepping into the public market. If you’ve been hearing the chatter about its Grey Market Premium (GMP) and wondering what it really means, here’s a simple breakdown.
The IPO Basics
Amanta Healthcare opened its IPO on September 1, 2025, and it runs until September 3.
- Issue Size: ₹126 crore (all fresh issue)
- Price Band: ₹120–₹126 per share
- Lot Size: 119 shares (minimum investment about ₹14,994 at the upper end)
- Listing: BSE and NSE around September 8–9
The money raised will mostly go into expanding its manufacturing capacity. That includes setting up new lines for its “SteriPort” sterile liquids and small-volume medicines, with the rest used for general corporate purposes.
What’s Happening with the GMP?
Here’s where it gets interesting. GMP is the extra price people in the grey market are willing to pay over the IPO price. It’s unofficial, but it gives a sense of demand.
- Early on, GMP was around ₹22, hinting at a listing near ₹148 (about 17–18% above issue price).
- Within hours of opening, GMP jumped to ₹28–₹29, suggesting a listing around ₹154–₹155—a 22–23% premium.
- Some reports pegged GMP lower, closer to 15%, showing how estimates can vary.
So, while the exact number depends on who you ask, the mood is clearly upbeat.
Why Are Investors Excited?
A few things are driving this strong premium:
- Rapid Subscription: The IPO was fully subscribed within 90 minutes of opening day. That’s a sign of serious demand.
- Anchor Investor Backing: Before the IPO went public, Amanta raised nearly ₹38 crore from big institutional investors, including Bandhan Mutual Fund. That kind of trust makes smaller investors more confident.
- Pharma Sector Tailwinds: Healthcare has been a strong theme in the markets, especially companies working on essential medicines.
- Reasonable Pricing: At ₹120–₹126 per share, analysts believe there’s still room for listing gains.
The Financial Picture
Looking at the numbers:
- Revenue dipped slightly from ₹281.6 crore in FY24 to ₹276.1 crore in FY25.
- Profit, however, shot up by 189%, with PAT at ₹10.5 crore in FY25 compared to ₹3.6 crore the previous year.
- Debt is on the higher side, with a debt-to-equity ratio of 2.02.
- At the upper price band, the valuation works out to about 34–46× earnings, which is higher than the industry average but lower than giants like Sun Pharma.
Risks Worth Noting
It’s easy to get carried away by GMP numbers, but investors should keep a few risks in mind:
- Single facility risk: All operations are concentrated in one manufacturing plant.
- High leverage: The company’s debt is relatively high compared to some peers.
- Unregulated GMP: Grey market activity is speculative and can swing quickly. What looks like a strong premium today could change by listing day.
Final Word
The Amanta Healthcare IPO has a lot going for it—sector relevance, strong demand, and a buzzing GMP of ₹28–₹29 that hints at a 20–23% gain. But remember, GMP is like street gossip in the market. It tells you the mood, not the outcome.
If you’re applying just for listing gains, the current GMP trend looks encouraging. If you’re investing long-term, it’s better to weigh the company’s fundamentals, profitability, and risks.
Either way, Amanta Healthcare’s debut has already captured market attention, and all eyes will be on its listing in the coming days.
| Disclaimer: The Indium Dossier publishes independent research for informational and educational purposes only. We do not provide any investment advice, brokerage services, or buy/sell/hold recommendations. All content, including articles, charts, and opinions, is based on publicly available information believed to be accurate at the time of publication. Readers are encouraged to perform their own analysis or consult with a licensed financial advisor before making investment decisions. The Indium Dossier, its authors, and affiliates shall not be held liable for any loss or damage arising from reliance on our content. All trademarks, logos, and brand names used in our materials are the property of their respective owners. |
Frequently Asked Questions
1. What is the Grey Market Premium (GMP) for Amanta Healthcare IPO?
As of opening day, the GMP was reported in the range of ₹28–₹29 per share, suggesting a potential listing gain of around 22–23%. Some reports also indicated lower premiums (around 15%), which shows GMP figures can vary depending on the source.
2. What is the price band and lot size for the Amanta Healthcare IPO?
The IPO price band is ₹120–₹126 per share, and the lot size is 119 shares. This means a minimum investment of about ₹14,994 at the upper price band.
3. When will Amanta Healthcare shares be listed?
The tentative listing date on BSE and NSE is around September 8–9, 2025, following allotment on September 4 and refunds/demat credits by September 8.